VYNE Therapeutics Inc.
Index- P/E- EPS (ttm)-1.43 Insider Own3.10% Shs Outstand53.55M Perf Week5.40%
Market Cap20.89M Forward P/E- EPS next Y-0.58 Insider Trans0.78% Shs Float52.72M Perf Month-19.00%
Income-73.30M PEG- EPS next Q-0.17 Inst Own25.50% Short Float2.98% Perf Quarter-27.31%
Sales14.80M P/S1.41 EPS this Y81.90% Inst Trans0.90% Short Ratio2.27 Perf Half Y-67.50%
Book/sh0.91 P/B0.44 EPS next Y42.60% ROA-78.70% Target Price5.80 Perf Year-89.02%
Cash/sh0.81 P/C0.49 EPS next 5Y- ROE-123.40% 52W Range0.34 - 4.24 Perf YTD-60.80%
Dividend- P/FCF- EPS past 5Y11.10% ROI-139.10% 52W High-90.57% Beta1.08
Dividend %- Quick Ratio3.00 Sales past 5Y85.40% Gross Margin77.30% 52W Low17.59% ATR0.04
Employees28 Current Ratio3.40 Sales Q/Q-46.50% Oper. Margin- RSI (14)39.55 Volatility10.61% 10.11%
OptionableYes Debt/Eq0.00 EPS Q/Q60.60% Profit Margin- Rel Volume0.53 Prev Close0.41
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume692.16K Price0.40
Recom2.00 SMA20-4.72% SMA50-26.60% SMA200-61.34% Volume365,812 Change-2.49%
Dec-06-21Resumed H.C. Wainwright Buy $7
May-18-22 08:00AM  
May-12-22 04:05PM  
May-10-22 08:00AM  
May-06-22 08:00AM  
May-05-22 02:06PM  
Apr-28-22 03:02PM  
Apr-07-22 08:00AM  
Mar-30-22 08:00AM  
Mar-17-22 08:00AM  
Mar-07-22 07:00AM  
Mar-03-22 08:00AM  
Jan-19-22 08:00AM  
Jan-13-22 07:00AM  
Jan-03-22 08:00AM  
Dec-13-21 12:08PM  
Nov-18-21 08:00AM  
Nov-12-21 01:09PM  
Nov-10-21 07:30AM  
Nov-04-21 08:00AM  
Oct-28-21 03:05PM  
Oct-26-21 08:00AM  
Oct-21-21 08:00AM  
Oct-19-21 08:00AM  
Oct-05-21 08:00AM  
Sep-20-21 08:00AM  
Sep-08-21 08:00AM  
Aug-13-21 07:11AM  
Aug-12-21 07:30AM  
Aug-11-21 08:43AM  
Aug-05-21 03:01PM  
Aug-02-21 08:00AM  
Jul-27-21 08:00AM  
Jul-19-21 08:00AM  
Jun-29-21 08:00AM  
Jun-08-21 09:34AM  
May-06-21 07:00AM  
Apr-28-21 08:00AM  
Apr-22-21 08:14AM  
Mar-04-21 04:01PM  
Mar-01-21 04:01PM  
Feb-18-21 10:16AM  
Feb-17-21 12:46AM  
Feb-16-21 12:02PM  
Feb-11-21 08:00AM  
Feb-01-21 08:00AM  
Jan-29-21 08:00AM  
Jan-26-21 07:59AM  
Jan-21-21 08:00AM  
Jan-05-21 08:00AM  
Dec-24-20 05:53AM  
Dec-17-20 08:00AM  
Dec-16-20 08:00AM  
Dec-15-20 08:00AM  
Dec-09-20 10:29PM  
Dec-01-20 08:00AM  
Nov-25-20 08:00AM  
Nov-09-20 12:47PM  
Nov-05-20 07:00AM  
Oct-28-20 08:00AM  
Oct-07-20 08:01AM  
Oct-01-20 07:01AM  
Sep-24-20 10:46AM  
Sep-23-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 08:35AM  
Sep-09-20 02:56PM  
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEPORE PATRICK GDirectorNov 30Buy1.0212,50012,69962,500Dec 02 05:08 PM
LEPORE PATRICK GDirectorAug 25Buy1.6012,50020,00050,000Aug 26 05:04 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 16Sale1.74250,000435,0004,935,057Aug 18 07:19 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 13Sale1.84250,000460,0005,185,057Aug 17 04:46 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 12Sale2.23338,897755,7405,435,057Aug 16 06:24 PM
LEPORE PATRICK GDirectorMay 26Buy3.6012,50044,95837,500May 27 05:18 PM